| scholarly article | Q13442814 |
| P2093 | author name string | Young-Suk Lim | |
| Yong Moon Shin | |||
| Dong Jin Suh | |||
| Han Chu Lee | |||
| Ju Hyun Shim | |||
| Seon-Ok Kim | |||
| Kang Mo Kim | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| hepatocellular carcinoma | Q1148337 | ||
| P304 | page(s) | 708-718 | |
| P577 | publication date | 2011-12-20 | |
| P1433 | published in | Radiology | Q3285690 |
| P1476 | title | Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models | |
| P478 | volume | 262 |
| Q28831507 | A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis |
| Q35984383 | Adipose-Derived Mesenchymal Stem Cell Exosomes Suppress Hepatocellular Carcinoma Growth in a Rat Model: Apparent Diffusion Coefficient, Natural Killer T-Cell Responses, and Histopathological Features |
| Q38697243 | Advances in Local and Systemic Therapies for Hepatocellular Cancer |
| Q37698184 | Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. |
| Q49498626 | Anti-angiogenic therapy in the setting of TACE: an elusive synergy? |
| Q41962614 | Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update |
| Q28086977 | Assessment of clinical and radiological response to sorafenib in hepatocellular carcinoma patients |
| Q38268169 | Assessment of radiologic response to targeted therapies in patients with hepatocellular carcinoma. |
| Q91683584 | Assessment of the response of hepatocellular carcinoma to interventional radiology treatments |
| Q59783545 | Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study |
| Q35843666 | CT Perfusion Imaging Can Predict Patients' Survival and Early Response to Transarterial Chemo-Lipiodol Infusion for Liver Metastases from Colorectal Cancers |
| Q38155505 | Chemoembolization in patients with hepatocellular carcinoma |
| Q87117255 | Chemoembolization of hepatocellular carcinoma |
| Q38406220 | Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma |
| Q53356745 | Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. |
| Q36416250 | Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach |
| Q86792380 | Comparison of contrast-enhanced ultrasound and contrast-enhanced computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST |
| Q57782407 | Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation |
| Q55020735 | Current guidelines for chemoembolization for hepatocellular carcinoma: Room for improvement? |
| Q90473382 | Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study |
| Q44481786 | Diagnosis of and therapy for hepatocellular carcinoma |
| Q36582635 | Does the Degree of Hepatocellular Carcinoma Tumor Necrosis following Transarterial Chemoembolization Impact Patient Survival? |
| Q49330012 | Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib |
| Q91830161 | Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma |
| Q53246536 | Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. |
| Q37183195 | Endovascular treatment of hepatocellular carcinoma with drug eluting microparticles (DC-Beads): CT evaluation of response to the treatment |
| Q40148438 | Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization. |
| Q64115269 | Evaluation of Early Response to Treatment of Hepatocellular Carcinoma with Yttrium-90 Radioembolization Using Quantitative Computed Tomography Analysis |
| Q96231885 | Evaluation of liver tumour response by imaging |
| Q90039181 | Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma |
| Q38265024 | Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. |
| Q36249520 | External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26 |
| Q50207399 | Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon-occluded transcatheter arterial chemoembolization: A retrospective cohort study |
| Q47877427 | Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Treated with Initial Transarterial Chemoembolization |
| Q37702238 | Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study |
| Q55312644 | Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization. |
| Q46291005 | Hepatocellular carcinomas within the Milan criteria: predictors of histologic necrosis after drug-eluting beads transarterial chemoembolization |
| Q28087066 | How I do it: Cone-beam CT during transarterial chemoembolization for liver cancer |
| Q37513083 | How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma |
| Q86095472 | Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update |
| Q90476391 | Imaging evaluation of sorafenib for treatment of advanced hepatocellular carcinoma |
| Q35568722 | Imaging for assessment of treatment response in hepatocellular carcinoma: Current update |
| Q38110203 | Intermediate hepatocellular carcinoma: current treatments and future perspectives |
| Q92356815 | Intermediate stage hepatocellular carcinoma: a summary review |
| Q35234472 | Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma |
| Q37143017 | Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma |
| Q57150838 | Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients |
| Q64101477 | Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma |
| Q57222484 | Long-term outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma |
| Q64229411 | MRI assessment of hepatocellular carcinoma after locoregional therapy |
| Q38857630 | New Approaches in Locoregional Therapies for Hepatocellular Carcinoma |
| Q36419100 | Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients |
| Q52985675 | Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE. |
| Q40333754 | Parametric response mapping of dynamic CT: enhanced prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization |
| Q51069032 | Predicting Outcomes After Chemo-Embolization in Patients with Advanced-Stage Hepatocellular Carcinoma: An Evaluation of Different Radiologic Response Criteria. |
| Q92379362 | Prediction of hepatocellular carcinoma response to 90Yttrium radioembolization using volumetric ADC histogram quantification: preliminary results |
| Q41372762 | Preliminary results of contrast-enhanced sonography in the evaluation of the response of uveal melanoma to gamma-knife radiosurgery. |
| Q35731141 | Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. |
| Q35106153 | Quantitative CT variables enabling response prediction in neoadjuvant therapy with EGFR-TKIs: are they different from those in neoadjuvant concurrent chemoradiotherapy? |
| Q36630342 | Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembo |
| Q42237455 | Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. |
| Q53167805 | Radiological-pathological correlation study of hepatocellular carcinoma undergoing local chemoradiotherapy and surgery. |
| Q38845317 | Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study |
| Q38164112 | Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel. |
| Q53173190 | Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. |
| Q56362861 | Restaging patients with hepatocellular carcinoma before additional treatment decisions: a multicenter cohort study |
| Q48189816 | Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model |
| Q26851627 | Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma |
| Q51598731 | Serum cell death biomarker mirrors liver cancer regression after transarterial chemoembolisation. |
| Q38929591 | Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study. |
| Q38888162 | Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres. |
| Q47121517 | The 4th Asia-Pacific Primary Liver Cancer Expert Meeting |
| Q46455135 | The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma |
| Q36528048 | The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization |
| Q26768460 | The Role of Diffusion-Weighted Imaging (DWI) in Locoregional Therapy Outcome Prediction and Response Assessment for Hepatocellular Carcinoma (HCC): The New Era of Functional Imaging Biomarkers |
| Q55100898 | The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection. |
| Q33686817 | The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). |
| Q58605600 | Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis |
| Q38923548 | Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy |
| Q27003849 | Transcatheter embolization therapy in liver cancer: an update of clinical evidences |
| Q50501948 | Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular Carcinoma. |
| Q33602716 | Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma |
| Q46792791 | mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). |
| Q30408237 | mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization |
Search more.